Ingalls & Snyder LLC Genmab A/S Transaction History
Ingalls & Snyder LLC
- $3.06 Billion
- Q3 2025
A detailed history of Ingalls & Snyder LLC transactions in Genmab A/S stock. As of the latest transaction made, Ingalls & Snyder LLC holds 107,274 shares of GMAB stock, worth $3.25 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
107,274
Previous 119,484
10.22%
Holding current value
$3.25 Million
Previous $2.47 Million
33.25%
% of portfolio
0.11%
Previous 0.09%
Shares
7 transactions
Others Institutions Holding GMAB
# of Institutions
282Shares Held
62.8MCall Options Held
58.8KPut Options Held
10.2K-
Orbis Allan Gray LTD Hamilton, D011.1MShares$335 Million1.89% of portfolio
-
Alliancebernstein L.P. New York, NY11MShares$331 Million0.11% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$154 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.82MShares$115 Million3.77% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.64MShares$110 Million0.08% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $19.9B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...